TG Therapeutics, Inc. reported strong Q3 results, with Briumvi revenues up 84% year-over-year and full-year guidance raised to $585 million. TGTX continues to expand Briumvi's market presence, driven

TG Therapeutics, Inc. (TGTX) Q3 2025 Earnings Call Transcript

11:56am, Monday, 03'rd Nov 2025

TG Therapeutics, Inc. ( TGTX ) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Chairman, CEO & P

TG Therapeutics (TGTX) Projected to Post Earnings on Monday

02:00am, Saturday, 01'st Nov 2025

TG Therapeutics (NASDAQ: TGTX - Get Free Report) is expected to announce its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect TG Therapeutics to post earnings of $0.24

TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update

07:30am, Friday, 31'st Oct 2025

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, November 3, 2025, at 8:30 AM ET to discuss results for th

TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI

07:30am, Tuesday, 28'th Oct 2025

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a conso

TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q3 Release

11:06am, Monday, 27'th Oct 2025

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Allspring Global Investments Holdings LLC Reduces Position in TG Therapeutics, Inc. $TGTX

03:47am, Friday, 24'th Oct 2025

Allspring Global Investments Holdings LLC trimmed its holdings in shares of TG Therapeutics, Inc. (NASDAQ: TGTX) by 5.5% during the second quarter, according to the company in its most recent Form 13F

New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment

09:10am, Wednesday, 24'th Sep 2025

During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

07:30am, Wednesday, 10'th Sep 2025

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients wit

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by

Tg Therapeutics Stock News

TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results

Why TG Therapeutics (TGTX) is a Top Growth Stock for the Long-Term

TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised

TG Therapeutics Q3 Earnings: Strong Quarter For Briumvi As CD20 Market Grows